Gamma-linolenic acid pathway

The gamma-linolenic acid pathway encompasses the biosynthesis, metabolism, and conversion of gamma-linolenic acid (GLA), an omega-6 polyunsaturated fatty acid. In humans, dietary linoleic acid is enzymatically desaturated (by delta-6 desaturase) to GLA, which is then elongated to dihommo-gamma-linolenic acid (DGLA) and subsequently converted to arachidonic acid. GLA and its derivatives serve as precursors to various eicosanoids, including prostaglandins and leukotrienes, which modulate inflammatory and immune responses. GLA also mediates tissue-specific roles, such as activating the retinoid X receptor (RXR) in neonatal heart development and energy metabolism. The pathway is significant in inflammation, cardiovascular, immune, and metabolic biology, and has therapeutic relevance for several diseases. However, the pathway itself is not a discrete molecular target for drugs; rather, GLA or enzymes within this pathway (e.g., delta-6 desaturase) may be considered actual targets in research and therapy.

Other names

GLA biosynthetic pathwayGLA metabolic pathwaygamma-linolenic acid metabolismGLA pathway

Dietary or supplemental GLA is incorporated into cell membranes or converted to anti-inflammatory mediators such as DGLA (dihomo-gamma-linolenic acid). DGLA-derived prostaglandins (e.g., PGE1) mediate anti-inflammatory, vasodilatory, and platelet anti-aggregation effects. GLA activation of RXR in heart tissue triggers genetic programs for mitochondrial and metabolic maturation (in neonates). Inhibition of pro-inflammatory leukotriene synthesis via metabolic shunting to anti-inflammatory lipids.